Saturday 17 October 2026
Export ARAV’s income statement to Excel — free account
ARAVIVE, INC
ARAV Healthcare Biotechnology
ARAVIVE, INC’s revenue for fiscal 2022 (year ended December 2022) was $9.1 million. Revenue growth for five consecutive years.
Follow ARAV
ARAVIVE, INC (ARAV) P/E ratio
ARAVIVE, INC has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (February 2024) to 8.5× (October 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| 11 more quarters | Free account |
Against its own ten years
Low 0.0×
High 8.5×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VIVS VivoSim Labs, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| ARAV ARAVIVE, INC | n/m |
| APVO Aptevo Therapeutics Inc. compare | 0.0× |
| ONCO Onconetix, Inc. compare | 0.0× |
| DCOY Decoy Therapeutics Inc compare | 0.0× |
| GRI GRI Bio, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)